April 10, 2025
434
5
1.15%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
28:54Now PlayingIn this episode of Beyond The Headline, anchor Sneha Koshy examines the fallout from U.S. President Donald Trump’s announcement of impending tariffs on pharmaceutical imports. With India supplying nearly 45% of generic drugs used in the U.S., the move could severely impact Indian drugmakers, who rely on the American market for up to 50% of their revenues.
Experts warn that the tariffs will raise production costs, erode price competitiveness, and lead to higher drug prices for American consumers.
A panel of experts has joined Sneha Koshy to discuss this in detail. Dharmesh Shah, BDR Pharma Chairman says “US is a conflicted pharma market which has helped them in keeping their healthcare bill down, India has played a significant role in API production.....” Another panelist Kenneth Moch, BioPharma Sector Expert says “Costs are going to rise with tariffs, there aren't many substitutes in pharma industry, the idea of bringing production back to US is difficult....”Watch the full discussion to know more and follow Mirror Now for the latest updates.
#pharmatariffs #trumppolicies #indiaustrade #genericdrugs #beyondtheheadline #snehakoshy #englishnews #latestnews #topnews #mirrornow SUBSCRIBE NOW |
For More Updates ►
Like us on Facebook ►
Follow us on Twitter ►
Follow us on Instagram ►
Subscribe to our other network channels:
Times Now Navbharat
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.